Cellular agriculture has long promised meat, seafood, dairy and eggs made without conventional farming, grown from cells or brewed by engineered microbes. Agronomics offers UK investors a listed route into that theme: rather than developing products itself, the AIM-quoted company assembles minority stakes in privately held cultivated-meat and precision-fermentation start-ups.

The Quick Version

  • Agronomics is a net-asset-value-driven investment company, not a product developer; returns depend on its private holdings, not its own science.
  • Reported NAV per share was 13.12p at 31 March 2026, with shares trading around a 52% discount to that figure.
  • Liberation Bioindustries (Liberation Labs) is the single largest position, followed by BlueNalu, SuperMeat, Onego Bio and Formo.
  • Portfolio milestones include Meatly's UK cultivated pet-food clearance and Onego Bio's US FDA 'no questions' letter, but Meatable was dissolved in December 2025.
  • Cash is modest, holdings are illiquid and privately valued, and sector economics remain unproven at scale.

What Agronomics Actually Does

Agronomics Limited is an investment company on AIM under ANIC (also traded in the US as AGNMF), co-founded by investor Jim Mellon, who chairs the board. It takes equity positions in early-stage businesses producing animal products without rearing or slaughtering animals. Crucially, it's a net-asset-value vehicle: its worth derives from a portfolio of unlisted holdings carried at directors' valuations, typically anchored to the price of the most recent third-party funding round.

What's In the Portfolio

The largest position at the December 2025 half-year was Liberation Bioindustries (Liberation Labs), a contract precision-fermentation manufacturer, at roughly 25% of NAV, following a Series A1 round in December 2025. BlueNalu (cultivated seafood) and SuperMeat (cultivated chicken) followed at around 12% and 11% respectively. Onego Bio (precision-fermentation egg-white protein) secured a US FDA 'no questions' GRAS letter in September 2025. Formo (dairy/cheese proteins) has products launched in European markets.

Other holdings include Mosa Meat, Umami Bioworks, Bond Pet Foods, Tropic (gene-edited bananas, which closed a $105m Series C in late 2025), All G (dairy casein, FDA 'no questions' letter April 2026), and Meatly (UK cultivated pet-food clearance, £10.4m Series A in May 2026). Meatable, previously a larger cultivated-meat position, was dissolved in December 2025 and written down in full — a reminder that individual holdings can fail outright.

The Numbers: NAV Down, Then a Partial Recovery

For the year to 30 June 2025, NAV per share fell to 12.34p from 15.58p, with a net operating loss of around £32.7m, driven principally by write-downs including the full Meatable impairment. The half-year to 31 December 2025 showed a partial recovery: NAV per share rose to 13.78p, net assets around £140m, and a net profit of about £10m, helped by investment gains. Cash was modest at about £2.15m.

The most recent quarterly update, at 31 March 2026, put NAV per share at 13.12p, net assets at approximately £138.7m and cash at £1.87m, with the share price around 6.3p — implying a discount to NAV of roughly 52%.

Why the Discount, and What It Might Mean

Retail and smaller institutional investors have few comparable public vehicles offering diversified exposure to private alternative-protein start-ups; most competing capital sits in private venture funds inaccessible to ordinary shareholders. But Agronomics competes for the best deals against well-resourced venture funds and sovereign wealth vehicles, and the persistent NAV discount constrains its options, since issuing new shares below asset value would dilute existing holders.

A wide discount can be read either as a margin of safety or as the market's scepticism about both the carrying valuations and the timeline to realisation — reasonable people can disagree on which.

Risks Worth Weighing

Valuation risk is foremost — private holdings are illiquid and carried at directors' estimates, so NAV can move sharply on new funding rounds or write-offs, as Meatable showed. Technology and commercialisation risk runs through the portfolio, since cost-competitive production at scale remains unproven for much of cultivated meat. Financing risk is acute for early-stage investees not yet profitable and dependent on continued fundraising in a cooler capital environment. Currency risk affects sterling-reported NAV given dollar and euro exposure, and concentration risk sits in the Liberation Bioindustries weighting.

What to Watch Next

Further regulatory clearances for portfolio companies, particularly first approvals for cultivated whole-cut products in major Western markets. Up-rounds that flow through to NAV, as recent Tropic financing showed. A realisation event — a trade sale or public listing of a significant holding — would provide hard evidence of value and cash to redeploy. Commercial supply agreements for precision-fermentation ingredients moving into food-industry supply chains.